August 27th 2025
A new suggests preimplantation genetic testing for aneuploidy can increase live birth rates in women aged 35 to 42 years.
Obesity Linked To Failed Induction, Increased Neonatal Morbidity
August 7th 2011The increasing epidemic of obesity affects all areas of obstetrics. Obesity is associated with medical, surgical, and obstetrical complications and higher rates of induction dysfunctional labor patterns. Since one-third of all reproductive-aged women are obese and almost 10% are extremely obese, this represents a significant problem for obstetricians. Thus, researchers from the division of maternal fetal medicine in the department of obstetrics and gynecology at University of Cincinnati College of Medicine in Ohio conducted a study to better understand the association between failed induction and obesity as well as to determine if the link is correlated with increasing class of obesity.
Read More
Clinical Guidelines for Evaluation and Management of Amenorrhea
August 5th 2011Definitions Primary amenorrheaFailure of menarche to occur when expected in relation to the onset of pubertal development. • No menarche by age 16 years with signs of pubertal development. • No onset of pubertal development by age 14 years. Secondary amenorrhea • Absence of menstruation for 3 or more months in a perviously mentruating women of reproductive age.
Read More
PROCLACTIN • Is a polypeptide hormone containing 198 amino acids and having a molecular weight of 22,000 daltons. • It curculates in different molecular sizes- a (small) form (mol wt 22,000), and a (big) form (mol wt 50,000), and an even larger (big-big) form (mol wt > 100,000). • The small form is biologically active, and about 80% of the hormone secreted is in this
Read More
New role for tamoxifen as fertility drug for breast cancer patients?
August 3rd 2011In a study published today in Europe's leading reproductive medicine journal Human Reproduction1, researchers from New York's Cornell University report the first IVF pregnancy to result from the use of tamoxifen as an ovarian stimulant.
Read More
Transdermal Contraceptive System: Clinical Management
August 3rd 2011Disclosure Declaration •Grant Support –National Institutes of Health, Ortho-McNeil Pharmaceutical, Inc, Pharmacia Corp., Berlex Laboratories, Proctor and Gamble •Honoraria and consultation fees –Ortho-McNeil Pharmaceutical, Inc., Berlex Laboratories, Pharmacia Corp., TAP Pharmaceuticals, Eli Lilly and Co. •Participation in company sponsored speakers’ bureau –Ortho-McNeil Pharmaceutical, Inc., Berlex Laboratories, Pharmacia Corp., Merck Pharmaceuticals.
Read More
Intra Uterine Contraceptive Devices (I.U.C.D.)
August 3rd 2011Presented by Dr. Narayan M. Patel M.D., D.G.O. FICSEmeritus Professor Muni. Medical collegePostal address-Mahalaxmi Institute of Medical Teaching,3, Shantiniketan park, Naranpura,Nr. Sardar Patel Colony,AHMEDABAD- 380 014 (Gujarat) INDIA E mail:- nmpatel1932@wilnetonline.net
Read More
A New Contraceptive Option: A Focus on the Transdermal Contraceptive System
A New Contraceptive Option: A Focus on the Transdermal Contraceptive System Ronald T. Burkman, MD Baystate Medical Center Tufts University School of Medicine
Read More